Pharmaceutical Executive Daily: September 17, 2025

Sep 17, 07:50 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

Share
Subscribe
Next
Pharmaceutical Executive Daily: September 18, 2025
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive